# US 7,745,689 B2 · Nephropathy-associated gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,689 B2
- Document ID: US7745689B2
- Status: Granted
- Kind: B2
- Application number: 10/545,276
- Filed: 2004-02-13
- Published: 2006-06-29
- Granted: 2010-06-29
- Earliest claimed: 2003-02-14
- Assignees: Akari Inada
- Inventors: Akari Inada; Atsushi Fukatsu; Yutaka Seino
- Web page: https://patentgrep.com/patent/US7745689B2

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- C07K 14/4703: {Inhibitors; Suppressors}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A nephropathy-associated gene which encodes a transcription repressor; and a nonhuman transgenic animal suffering from nephropathy which is constructed by transferring the above gene and allows the observation of increases in urinary volume, urinary albumin and urinary NAG, pyelectasis, enlargement in kidney tubule and glomerular swelling at the early stage and the following sclerosis.

## Claims

### Claim 1

A transgenic mouse comprising either 4 or 6 copies of transgenes encoding inducible cAMP early repressor Iγ (ICER Iγ) operably linked to a human insulin promoter; wherein the transgenic mouse develops nephropathy.

### Claim 2 (depends on 1)

The transgenic mouse according to claim 1, wherein the nephropathy is diabetic nephropathy.

### Claim 3 (depends on 1)

The transgenic mouse according to claim 1, wherein the copy number of said transgene is 6.

### Claim 4 (depends on 1)

A method for screening a therapeutic substance for at least one condition selected from the group consisting of nephropathy, diabetic nephropathy and diabetes, comprising a step of administering a subject substance to the transgenic mouse according to claim 1 and measuring an effect of the subject substance on the at least one condition selected from the group consisting of nephropathy, diabetic nephropathy and diabetes of the mouse.